An investigation for investors in Conatus Pharmaceuticals Inc (NASDAQ:CNAT) shares over potential securities laws violations by Conatus Pharmaceuticals was announced and NASDAQ:CNAT stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 03/10/2015 -- An investigation on behalf of investors of Conatus Pharmaceuticals Inc (NASDAQ:CNAT) shares over potential securities laws violations by Conatus Pharmaceuticals and certain of its directors and officers in connection certain financial statements was announced.
Investors who purchased shares of Conatus Pharmaceuticals Inc (NASDAQ:CNAT) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Conatus Pharmaceuticals Inc (NASDAQ:CNAT) concerning whether a series of statements by Conatus Pharmaceuticals regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
On March 5, 2015, Conatus Pharmaceuticals Inc disclosed that on March 2, 2015, Gary C. Burgess, M.B., Ch.B. M.Med., tendered his resignation as Senior Vice President, Clinical Research and Chief Medical Officer of Conatus Pharmaceuticals Inc., effective April 2, 2015. Shares of Conatus Pharmaceuticals Inc (NASDAQ:CNAT) declined to as low as $5.61 per share on March 6, 2015.
Those who purchased shares of Conatus Pharmaceuticals Inc (NASDAQ:CNAT) have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com